Windlas Biotech Limited (WINDLAS.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹878.50 (-0.45%) as of
Key statistics
- Market cap
- 18.13B
- P/E (TTM)
- 28.42
- EPS (TTM)
- 30.91
- Dividend yield
- 0.71%
- 52-week range
- 697.40 – 1,181.90
- Beta
- 0.26
- Revenue (TTM)
- 9.42B
- Profit margin
- 7.05%
- Volume
- 22.38k
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. The company sells generic medicines, health supplements, and custom-branded formulations under Windlas brand names. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Dehradun, India
- Employees
- 1,385
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.